新型2-罗利衍生物作为含有GluN2B的NMDA受体的负基调剂
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
研究人员开发了新型的2-pyrrolidone衍生物作为含有GluN2B的N-甲基-D-酸受体 (NMDARs) 的负基调节剂. 这些化合物提供了更好的代谢稳定性,针对潜在的治疗应用的ifenprodil结合部位.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- N-甲基-D-酸受体 (NMDARs),特别是那些含有GluN2B亚单元的受体,与各种神经系统疾病有关.
- 对NMDARs的度调节提供了一个有前途的治疗策略.
- 现有的调节剂,如化合物,经常面临代谢稳定性的挑战.
研究的目的:
- 引入新型的2-pyrrolidone衍生物作为潜在的治疗剂.
- 将这些化合物描述为含有GluN2B的NMDARs的负基调制剂 (NAM).
- 评估这些新型化合物的代谢稳定性.
主要方法:
- 一系列新型2-罗利衍生物的合成.
- 在含有GluN2B的NMDAR中药理学评估化合物的活性.
- 与现有药物相比,对代谢稳定性的评估.
主要成果:
- 新型的2-皮罗利衍生物有效地作为含有GluN2B的NMDARs的NAM.
- 这些化合物特别针对NMDA受体上的ifenprodil结合部位.
- 开发的衍生品表现出比传统的基于的分子更强大的代谢稳定性.
结论:
- 新的2-罗利衍生物代表了一个有前途的新类NMDAR调节剂.
- 它们改善的新陈代谢稳定性表明它们有可能增强药理动力学特征.
- 这些发现支持进一步研究神经疾病治疗的发展.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Antipsychotic Drugs: Typical and Atypical Agents
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
